{"id":"mirikizumab-intravenous-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL3990014","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mirikizumab binds to the p19 subunit of IL-23, a key cytokine involved in driving Th17 cell differentiation and inflammatory responses. By blocking IL-23, the drug suppresses pathogenic T-cell responses implicated in autoimmune and inflammatory diseases. This mechanism is distinct from IL-12/23 inhibitors and provides selective IL-23 pathway inhibition.","oneSentence":"Mirikizumab is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:20.596Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT04844606","phase":"PHASE3","title":"A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-05-26","conditions":"Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases","enrollment":150},{"nctId":"NCT07483073","phase":"PHASE2","title":"A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-04","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":60},{"nctId":"NCT07483099","phase":"PHASE2","title":"A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-04","conditions":"Crohn Disease","enrollment":60},{"nctId":"NCT06864403","phase":"PHASE4","title":"Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-08-12","conditions":"Pouchitis, Pouches, Ileoanal, Pouch, Ileal","enrollment":25},{"nctId":"NCT03524092","phase":"PHASE3","title":"A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-10-19","conditions":"Ulcerative Colitis","enrollment":1177},{"nctId":"NCT03518086","phase":"PHASE3","title":"An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-06-18","conditions":"Ulcerative Colitis","enrollment":1281},{"nctId":"NCT04004611","phase":"PHASE2","title":"A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-05-18","conditions":"Ulcerative Colitis","enrollment":26},{"nctId":"NCT03053622","phase":"PHASE1","title":"A Study of Mirikizumab (LY3074828) Injection in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-04-24","conditions":"Healthy","enrollment":67},{"nctId":"NCT04137380","phase":"PHASE1","title":"A Study of Mirikizumab in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-04","conditions":"Healthy","enrollment":60},{"nctId":"NCT03220126","phase":"PHASE1","title":"A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-17","conditions":"Healthy","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omvoh","LY3074828"],"phase":"marketed","status":"active","brandName":"Mirikizumab - Intravenous (IV)","genericName":"Mirikizumab - Intravenous (IV)","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in immune-mediated diseases. Used for Ulcerative colitis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}